<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29589535</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1873-4286</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>14</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current pharmaceutical design</Title>
          <ISOAbbreviation>Curr Pharm Des</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling Pathways in Inflammation and Anti-inflammatory Therapies.</ArticleTitle>
        <Pagination>
          <StartPage>1449</StartPage>
          <EndPage>1484</EndPage>
          <MedlinePgn>1449-1484</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1381612824666180327165604</ELocationID>
        <Abstract>
          <AbstractText>During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yeung</LastName>
            <ForeName>Yiu To</ForeName>
            <Initials>YT</Initials>
            <AffiliationInfo>
              <Affiliation>China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aziz</LastName>
            <ForeName>Faisal</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerrero-Castilla</LastName>
            <ForeName>Angelica</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, Casilla 121, Iquique 1100000, Chile.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arguelles</LastName>
            <ForeName>Sandro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Pharm Des</MedlineTA>
        <NlmUniqueID>9602487</NlmUniqueID>
        <ISSNLinking>1381-6128</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IL-6</Keyword>
        <Keyword MajorTopicYN="Y">Inflammation</Keyword>
        <Keyword MajorTopicYN="Y">JAK/STAT</Keyword>
        <Keyword MajorTopicYN="Y">PI3K</Keyword>
        <Keyword MajorTopicYN="Y">anti-inflammatory drug</Keyword>
        <Keyword MajorTopicYN="Y">hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">p38 MAPK.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29589535</ArticleId>
        <ArticleId IdType="doi">10.2174/1381612824666180327165604</ArticleId>
        <ArticleId IdType="pii">CPD-EPUB-89351</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29589535</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1873-4286</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>14</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current pharmaceutical design</Title>
          <ISOAbbreviation>Curr Pharm Des</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling Pathways in Inflammation and Anti-inflammatory Therapies.</ArticleTitle>
        <Pagination>
          <StartPage>1449</StartPage>
          <EndPage>1484</EndPage>
          <MedlinePgn>1449-1484</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/1381612824666180327165604</ELocationID>
        <Abstract>
          <AbstractText>During the past decade, an abundance of new evidence highlighted the importance of inflammation in the development of chronic pathologies such as neurodegeneration, cancer, diabetes, cardiovascular disease and inflammatory bowel disease. However, most of the current therapies do not address the underlying problem and better therapies are urgently needed. A growing number of researchers have discovered various signaling pathways that are associated with the initiation and progression of inflammation. Among different pathways, we will focus on three classical inflammatory pathways: p38 MAPK, IL-6/JAK/STAT3 and PI3K; and a non-classical inflammatory pathway, the Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as FoxO1/3, TNFα, IL-6, COX2, HIF-1α, AP-1, JAK and STAT. In this review, the molecular mechanisms, associated pathologies and selected drugs (both preclinical and clinical) of these signaling pathways will be summarized. Finally, limitations and potential risks of anti-inflammatory drugs will also be discussed.</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yeung</LastName>
            <ForeName>Yiu To</ForeName>
            <Initials>YT</Initials>
            <AffiliationInfo>
              <Affiliation>China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aziz</LastName>
            <ForeName>Faisal</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>China-US (Henan) Hormel Cancer Institute, Zhengzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerrero-Castilla</LastName>
            <ForeName>Angelica</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Quimica y Farmacia, Facultad de Ciencias de la Salud, Universidad Arturo Prat, Casilla 121, Iquique 1100000, Chile.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arguelles</LastName>
            <ForeName>Sandro</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Pharm Des</MedlineTA>
        <NlmUniqueID>9602487</NlmUniqueID>
        <ISSNLinking>1381-6128</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IL-6</Keyword>
        <Keyword MajorTopicYN="Y">Inflammation</Keyword>
        <Keyword MajorTopicYN="Y">JAK/STAT</Keyword>
        <Keyword MajorTopicYN="Y">PI3K</Keyword>
        <Keyword MajorTopicYN="Y">anti-inflammatory drug</Keyword>
        <Keyword MajorTopicYN="Y">hippo pathway</Keyword>
        <Keyword MajorTopicYN="Y">p38 MAPK.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29589535</ArticleId>
        <ArticleId IdType="doi">10.2174/1381612824666180327165604</ArticleId>
        <ArticleId IdType="pii">CPD-EPUB-89351</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
